Travere Therapeutics (TVTX) Non-Current Deferred Tax Liability (2013 - 2017)

Travere Therapeutics (TVTX) has 5 years of Non-Current Deferred Tax Liability data on file, last reported at $16.8 million in Q4 2017.

• Quarterly Non-Current Deferred Tax Liability fell 65.48% year-over-year to $16.8 million in Q4 2017, while the trailing twelve-month figure through Dec 2017 was $16.8 million (down 65.48% YoY) and the FY2017 annual result came in at $16.8 million, down 65.48% from the prior year.
• Non-Current Deferred Tax Liability advanced to $16.8 million in Q4 2017, from $1.2 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $48.7 million in Q4 2016 to a low of $141000.0 in Q4 2014.
• A 5-year average of $14.6 million and a median of $12.1 million in 2016 frame the typical range for Non-Current Deferred Tax Liability.
• Annual changes were most pronounced in 2014 — Non-Current Deferred Tax Liability slumped 94.58% — and 2015, when it jumped 17153.9%.
• Tracing TVTX's Non-Current Deferred Tax Liability over 5 years: stood at $2.6 million in 2013, then tumbled by 94.58% to $141000.0 in 2014, then jumped by 17153.9% to $24.3 million in 2015, then surged by 100.18% to $48.7 million in 2016, then slumped by 65.48% to $16.8 million in 2017.
• The last three Non-Current Deferred Tax Liability figures came in at $16.8 million (Q4 2017), $1.2 million (Q2 2017), and $4.4 million (Q1 2017), per Business Quant data.